PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-3.71%
Negative revenue growth while 3088.T stands at 1.89%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-2.36%
Negative gross profit growth while 3088.T is at 1.82%. Joel Greenblatt would examine cost competitiveness or demand decline.
-17.14%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-16.80%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-17.89%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-17.88%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-17.88%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-0.00%
Share reduction while 3088.T is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3088.T is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
27.78%
Similar 10Y revenue/share CAGR to 3088.T's 30.24%. Walter Schloss might see both firms benefiting from the same long-term demand.
-5.26%
Negative 5Y CAGR while 3088.T stands at 22.67%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-31.58%
Negative 3Y CAGR while 3088.T stands at 14.97%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
No Data
No Data available this quarter, please select a different quarter.
99.93%
Net income/share CAGR at 75-90% of 3088.T's 121.18%. Bill Ackman would press for strategic moves to boost long-term earnings.
12.21%
Below 50% of 3088.T's 49.83%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-34.86%
Negative 3Y CAGR while 3088.T is 28.95%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
94.36%
Equity/share CAGR of 94.36% while 3088.T is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
32.39%
5Y equity/share CAGR at 50-75% of 3088.T's 58.13%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
-14.03%
Negative 3Y equity/share growth while 3088.T is at 38.98%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.00%
Negative near-term dividend growth while 3088.T invests at 100.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
14.81%
Our AR growth while 3088.T is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
8.28%
We show growth while 3088.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
9.75%
Asset growth above 1.5x 3088.T's 2.17%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
4.09%
BV/share growth above 1.5x 3088.T's 1.17%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
113.93%
We have some new debt while 3088.T reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
2.04%
SG&A growth well above 3088.T's 3.19%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.